Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
No measuring, no mixing, no mess
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpoint In ACHIEVE-5, orforglipron lowered A1C by an additional 2.1% when taken with insulin glargine, meeting the primary endpoint 1,2,3 "Orforglipron has now demonstrated superiority over two active comparators in clinical trials for type 2 diabetes," said In both trials, the overall safety and tolerability profile of orforglipron, as well as treatment discontinuation rates, were consistent with previous studies
Key Features of CJC-1295 No DAC: CJC-1295 No DAC acts as an analog of the growth hormone-releasing hormone (GHRH), stimulating the pituitary gland to produce and release more natural growth hormone
A few possible relevant articles were excluded due to language issues
and Miguel Servet research contract CP20/00080 (Instituto de Salud Carlos III
US$ 20.91
US$ 21.20
US$ 26.17
